These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29313952)

  • 1. How to Consider Rare Genetic Variants in Personalized Drug Therapy.
    Lauschke VM; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2018 May; 103(5):745-748. PubMed ID: 29313952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.
    Arbitrio M; Di Martino MT; Scionti F; Agapito G; Guzzi PH; Cannataro M; Tassone P; Tagliaferri P
    Oncotarget; 2016 Aug; 7(33):54028-54050. PubMed ID: 27304055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics.
    Santos M; Niemi M; Hiratsuka M; Kumondai M; Ingelman-Sundberg M; Lauschke VM; Rodríguez-Antona C
    Genet Med; 2018 Jun; 20(6):622-629. PubMed ID: 29261188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.
    Lauschke VM; Milani L; Ingelman-Sundberg M
    AAPS J; 2017 Nov; 20(1):4. PubMed ID: 29181807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Databases in the area of pharmacogenetics.
    Sim SC; Altman RB; Ingelman-Sundberg M
    Hum Mutat; 2011 May; 32(5):526-31. PubMed ID: 21309040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia.
    Koutsilieri S; Tzioufa F; Sismanoglou DC; Patrinos GP
    Pharmacol Res; 2020 Mar; 153():104590. PubMed ID: 31830522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic content of commercial genome-wide genotyping arrays.
    Lemieux Perreault LP; Zaïd N; Cameron M; Mongrain I; Dubé MP
    Pharmacogenomics; 2018 Oct; 19(15):1159-1167. PubMed ID: 30272537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.
    Božina N; Vrkić Kirhmajer M; Šimičević L; Ganoci L; Mirošević Skvrce N; Klarica Domjanović I; Merćep I
    Croat Med J; 2020 Apr; 61(2):147-158. PubMed ID: 32378381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized Pharmacotherapy Utilizing Genetic Biomarkers and Novel In Vitro Systems As Predictive Tools for Optimal Drug Development and Treatment.
    Ingelman-Sundberg M; Lauschke VM
    Drug Metab Dispos; 2024 May; 52(6):467-475. PubMed ID: 38575185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of pharmacogenetics of adverse drug reactions in elderly people.
    Cardelli M; Marchegiani F; Corsonello A; Lattanzio F; Provinciali M
    Drug Saf; 2012 Jan; 35 Suppl 1():3-20. PubMed ID: 23446782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care.
    Trent RJ; Cheong PL; Chua EW; Kennedy MA
    Pathology; 2013 Jun; 45(4):357-70. PubMed ID: 23594690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing.
    Lauschke VM; Ingelman-Sundberg M
    Eur J Pharm Sci; 2019 Mar; 130():65-77. PubMed ID: 30684656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].
    Stingl JC; Just KS; Kaumanns K; Schurig-Urbaniak M; Scholl C; von Mallek D; Brockmöller J
    Internist (Berl); 2016 Mar; 57(3):289-97. PubMed ID: 26830424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future prospects for pharmacogenetics in the quest for personalized medicine.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2012 Dec; 50(12):13-6. PubMed ID: 23457712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
    Ross CJ; Visscher H; Sistonen J; Brunham LR; Pussegoda K; Loo TT; Rieder MJ; Koren G; Carleton BC; Hayden MR;
    Thyroid; 2010 Jul; 20(7):681-7. PubMed ID: 20578893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital.
    La Russa R; Fineschi V; Di Sanzo M; Gatto V; Santurro A; Martini G; Scopetti M; Frati P
    Curr Pharm Biotechnol; 2017; 18(3):274-281. PubMed ID: 28176638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single Nucleotide Polymorphisms as Genomic Markers for High-Throughput Pharmacogenomic Studies.
    Lonetti A; Fontana MC; Martinelli G; Iacobucci I
    Methods Mol Biol; 2016; 1368():143-59. PubMed ID: 26614074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly personalized reports for personalized drug selection by expert systems as clinical decision support.
    Hizel HC
    Per Med; 2017 Mar; 14(2):93-97. PubMed ID: 29754552
    [No Abstract]   [Full Text] [Related]  

  • 19. Personalized Therapeutics and Pharmacogenomics: Integral to Personalized Health Care.
    Sadee W
    Pharm Res; 2017 Aug; 34(8):1535-1538. PubMed ID: 28493098
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenomics: Prescribing Precisely.
    Wake DT; Ilbawi N; Dunnenberger HM; Hulick PJ
    Med Clin North Am; 2019 Nov; 103(6):977-990. PubMed ID: 31582008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.